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A B S T R A C T
Background: The most critical adverse effects of class III drugs are marked QT prolongation and torsade de
pointes. Even though intravenous amiodarone (iv-Amio) is a representative class III drug, it peculiarly
inhibits both clinical ventricular tachycardia/ﬁbrillation (VT/VF) and proarrhythmic effects.
To test the hypothesis that iv-Amio homogeneously prolongs repolarization, we evaluated
electrocardiographic changes before and during short-term amiodarone therapy, focusing closely on
the ventricular dispersion of repolarization.
Methods: Twenty-seven consecutive patients treated with iv-Amio for VT/VF as a ﬁrst-line
antiarrhythmic therapy were enrolled in this study. Twelve-lead electrocardiography was recorded
before and during amiodarone therapy to evaluate the following electrocardiographic intervals: R–R,
QRS, QT, QRS to T-peak (QTp), and T-peak to T-end (Tp-e; as an index of dispersion of repolarization).
Repolarization indices were corrected to the heart rate by Bazett’s method (QTc, c-QTp, c-Tp-e).
Results: Amiodarone suppressed VT/VF in 19/27 (70%) patients without conferring any proarrhythmic
effect. The QTc, c-QTp, and R–R interval were signiﬁcantly prolonged during amiodarone (476  45 ms vs
511  45 ms, p < 0.05; 338  40 ms vs 364  35 ms, p < 0.05; 762  272 ms vs 870  189 ms, p < 0.05;
respectively), whereas the c-Tp-e and QRS durations did not change signiﬁcantly (139  33 ms vs
145  41 ms, p = 0.25; 96  20 ms vs 97  21 ms, p = 0.33; respectively).
Conclusions: Iv-Amio homogeneously prolongs repolarization and properly inhibits original VT/VF
recurrence without inducing torsade de pointes.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Intravenous amiodarone (iv-Amio) is one of the most widely
recommended antiarrhythmic treatments for preventing the
recurrence of malignant ventricular tachyarrhythmia. Cardiolo-
gists widely use it as a ﬁrst-line therapy in the critical setting of
malignant ventricular tachycardia (VT) or ventricular ﬁbrillation
(VF) [1]. Amiodarone has long been described as a prototype
channel blocker targeting the delayed rectiﬁer K currents (IK), yet
the effects on the IK channel are complex and remain controversial
[2]. The IK currents are important determinants of cardiac* Corresponding author at: Division of Cardiology, Department of Medicine,
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsrepolarization and can be broadly divided into two distinctive
components: a rapidly activating component (IKr) and slowly
activating component (IKs) [3]. When Bosch et al. administered
amiodarone to guinea pigs by intraperitoneal injection, the current
densities of both IKr and IKs were substantially reduced in
ventricular myocytes, and the levels of reduction were similar
between the two components [4]. Kamiya et al., on the other hand,
found that a short-term application of amiodarone brought about a
signiﬁcant reduction of IKr vs only a minimal reduction of IKs in
rabbit ventricular myocytes. Kamiya’s group also observed unique
differential effects of amiodarone on the two IK components when
they administered the drug for different durations: short-term
treatment inhibited primarily IKr, whereas long-term treatment
reduced IKs [5]. Several experimental studies have clearly shown
differences in the effects of IKs- and IKr-blocking agents on the
repolarization process (phase 2–3) [6,7]. According to these reserved.
Y. Kotake et al. / Journal of Cardiology 66 (2015) 161–167162investigations, IKs blockers prolong the action potential duration
(APD) throughout different layers or different sites of the ventricle
with high uniformity without expanding the T wave or dispersion
of repolarization [6,8]. The IKr blocker, on the other hand,
preferentially prolongs cells that start out with longer APDs, and
thereby elicits an increased dispersion of repolarization leading to
torsade de pointes (TdP) [7,8]. Clinical investigators, mainly from
Japan, have found that the pure IKr channel blocker nifekalant
suppresses VT or VF, but it provides marked QT prolongation with
an increased dispersion of repolarization, and ultimately TdP, in
3.9–17% of the patients [9,10]. On the contrary, iv-Amio rarely
induces TdP [11]. To the best of our knowledge, few studies have
demonstrated why iv-Amio confers such well-balanced effects in
patients with life-threatening ventricular tachyarrhythmia.
Our group hypothesized that iv-Amio inhibits both VT/VF (the
conditions it targets) and proarrhythmic effect (long-QT-related
TdP) by prolonging repolarization in a homogeneous and modest
fashion. We tested this hypothesis by evaluating detailed
electrocardiographic (ECG) changes before and during short-term
amiodarone therapy, especially the dispersion of repolarization.
Methods
Study participants
We retrospectively enrolled consecutive patients with life-
threatening VT/VF in whom iv-Amio was administered continu-
ously as a ﬁrst-line antiarrhythmic therapy at our institutions
between December 2009 and April 2014. To observe a purer
pharmacologic action of iv-Amio, VT/VF patients who had received
any class I or III drug therapy before amiodarone therapy or had
failed to recover from cardiac arrest before amiodarone therapy
were excluded. Patients who received continuous iv-Amio for
less than 6 h were also excluded, as the ionic action and clinical
efﬁcacy of the agents were difﬁcult to evaluate in such a short time.
Patients who had received previous beta-blockers or calcium
antagonists were accepted in the study, as these agents confer only
minor effects on ventricular repolarization.
Clinical variables
Several clinical variables [i.e. age, gender, body mass index
(BMI), underlying heart disease, left ventricular ejection fraction
(LVEF), type of ventricular tachyarrhythmia (VT or VF), serum
electrolytes, previous beta-blocker administration, and cumulative
dose and efﬁcacy of iv-Amio] were collected and evaluated in
relation to the changes of the ECG parameters.
Administration protocol
Iv-Amio was administered according to the standard protocol,
with an initial rapid infusion of 125 mg for 10 min, followed by a
6-h loading infusion of 40 mg/h, followed by maintenance infusion
of 20 mg/h thereafter. In patients with low blood pressure
(<100 mmHg) or very low LVEF (<25%), the treatment was
sometimes commenced at the loading dose without administering
an initial rapid infusion. The cumulative dose of amiodarone
administered intravenously (at the time the physicians deter-
mined the efﬁcacy of the drug) within 48 h was calculated. The
protocol for this study was approved by the ethical committee of
the Kinki University School of Medicine in 2014.
ECG recordings
A standard 12-lead ECG was recorded before and during
iv-Amio administration. ECG recordings were obtained between6 and 48 h after the amiodarone administration was commenced.
Among the several ECG recordings taken during amiodarone
therapy, we selected the recording obtained when the physicians
made a decision whether the drug was effective or not. The mean
interval from the initiation of amiodarone to the selected ECG
recording was 21  14 h.
Measurement of ECG parameters
According to evidence from several experimental studies, the
cells with the shortest action potential repolarize at the peak of the
T wave and the cells with the longest action potential repolarize at
the end of the T wave [12,13]. Hence, the dispersion of
repolarization can be estimated by measuring the interval from
the peak of the T wave to the end of the T wave (Tp-e). Here we
sought to clearly determine the end of the T wave by manually
measuring the following ECG parameters in all six precordial ECG
leads with the amplitude of T wave 0.2 mV (Fig. 1). The QT
interval was deﬁned as the time interval between the QRS onset
and the point at which the isoelectric line intersected a tangential
line visually drawn at the minimum ﬁrst derivative point of the
positive T wave or at the maximum point of the negative T wave.
In a case with a bifurcated or secondary T wave (pathological
U wave), it was included as part of the measurement of the QT
interval. When, on the other hand, a normal U wave apparently
separate from the T wave appeared, it was not included. The Q–T
peak interval (QTp) was deﬁned as the time interval between the
QRS onset and the point at the peak of T wave. When a T wave had a
biphasic or a notched conﬁguration, the peak of the T wave was
deﬁned as that of the dominant T wave deﬂection. Tp-e was
deﬁned as the time interval between QTp to the end of the T wave.
The QT, QTp, and Tp-e (as an index of repolarization) were
corrected to the heart rate by Bazett’s method (QTc; QT/HRR,
c-QTp; QTp/HRR, c-Tp-e; Tp-e/HRR). The QRS duration was also
measured at all leads in which QT interval parameters were
obtained. The averaged QTc in the particular selected leads during
amiodarone minus those before amiodarone in all patients was
deﬁned as DQTc. In three patients with atrial ﬁbrillation, the QTc
intervals following the shortest and longest R–R intervals were
respectively measured and averaged (corrected by the square roots
of the HRR values immediately preceding them) [14].
To minimize the measurement error and bias, each ECG
parameter was independently measured by three different skilled
cardiologists without knowledge of the case status. The Grubbs–
Smirnovs test was used to conﬁrm the absence of extreme values
among the measurements by the three examiners before detailed
analysis. Each ECG parameter was expressed as an average of three
values measured independently.
Efﬁcacy of amiodarone
A successful response to amiodarone was deﬁned as no further
VT episodes lasting more than 15 beats, no hemodynamically
unstable VT/VF at any point during drug infusion therapy between
6 and 48 h, and no adverse effects requiring early termination of
the drug.
Statistics
All data are presented as means  SD. A paired t-test was used for
comparisons of ECG variables (QRS interval, QTc, c-QTp, c-Tp-e, and
R–R interval) between before and during administration of amiodar-
one, with signiﬁcance assumed for p-values of 0.05 or less. Univariate
logistic regression analyses were used to search for factors associated
with QTc change (DQTc). The following factors were evaluated:
age, gender, BMI, underlying heart disease, LVEF, type of ventricular
Fig. 1. Twelve-lead electrocardiogram (ECG) before and during amiodarone infusion in a case with old myocardial infarction and sustained ventricular tachycardia (case 13).
The peak and the end of T wave are indicated by the arrows. All ECG parameters were measured in all precordial leads except for V4. QTc, c-QTp, c-Tp-e in lead V2 were
prolonged (509–521 ms, 364–366 ms, and 145–155 ms, respectively) and these values are almost identical throughout the leads. QTp, QRS to T-peak; Tp-e, T-peak to T-end;
repolarization indices were corrected to the heart rate by Bazett’s method (QTc, cQTp, cTp-e).
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and the cumulative dose and efﬁcacy of amiodarone. Next, a
multivariate logistic regression analysis was performed on variables
with p-values of less than 0.05 in the ﬁrst univariate analysis, together
with several other parameters with conceivable links to QTc change.
Results
Patients
We retrospectively collected 42 consecutive patients with life-
threatening VT/VF in whom iv-Amio was administered continu-
ously between December 2009 and April 2014 in our departments.
In order to evaluate exact and purer pharmacologic action of
iv-Amio, we excluded 15 VT/VF patients because of the following
reasons: any class I or III drugs administered before amiodarone
therapy (n = 11), no control recording of 12-lead ECG before
iv-Amio (n = 2), and less than 6 h continuation of iv-Amio (n = 2).
As a result, we enrolled 27 patients with life-threatening VT/VF
who underwent iv-Amio administered continuously (>6 h) as a
ﬁrst-line antiarrhythmic therapy. Their pathologies were sustained
VT or VF associated with coronary artery disease (20 patients),
hypertrophic cardiomyopathy (2 patients), non-ischemic dilated
cardiomyopathy (1 patient), valvular heart disease (1 patient),
hypertensive heart disease (1 patient), and idiopathic VF
(2 patients). The mean patient age was 71  12 years and the
male/female ratio was 14/13. LVEF varied from 17% to 74% and had a
mean value of 42  16% (Table 1).
Efﬁcacy and side effects of amiodarone
Amiodarone was effective in suppressing recurrence of malig-
nant ventricular tachyarrhythmia in 19 of the 27 patients (70%,
Table 1). None of the patients developed proarrhythmic TdP,
hemodynamic deterioration, or signiﬁcant liver or lung toxicities
during amiodarone therapy. The total mortality rate over the 7-day
period immediately following amiodarone therapy was 11% (0% in
responders and 38% in non-responders).ECG parameters
Fig. 1 illustrates ECG before and during amiodarone infusion in
a case with old myocardial infarction and sustained VT (case 13). In
this case, sufﬁcient amplitude of T wave in all precordial leads
except for V4 allowed us to determine the peak and the end of
T wave clearly, and showed that all the parameters (QTc, c-QTp,
c-Tp-e) were almost identical throughout the leads. Correspond-
ingly, there was no apparent dispersion of QTc interval among
precordial leads before and during amiodarone in all patients.
Together with homogeneous QT prolongation, there was no
marked T wave morphological change (i.e. degeneration to bizarre
or inverted T wave) except for one patient, who exhibited a polarity
inversion of the T wave during amiodarone (case 20). Therefore,
we were able to utilize the same lead with the largest T wave
amplitude for comparison of T wave parameters before and during
amiodarone. Fig. 2 shows changes in QTc, c-QTp, and c-Tp-e
intervals before and during amiodarone in selected leads from two
other cases (cases 9 and 27). In panel A, apparent prolongation was
observed in QTc and c-QTp (508–537 ms and 370–394 ms,
respectively) without signiﬁcant change in c-Tp-e (139–143 ms).
In panel B, c-QTp and c-Tp-e were equally prolonged (312–334 ms
and 114–134 ms, respectively), but no extreme prolongation of c-
Tp-e was found. Overall, as shown in Figs. 3 and 4, the QTc, c-QTp,
and R–R interval were signiﬁcantly prolonged during amiodarone
(476  45 ms vs 511  45 ms, p < 0.05; 338  40 ms vs 364  35 ms,
p < 0.05; 762  272 ms vs 870  189 ms, p < 0.05; respectively),
whereas the c-Tp-e and QRS duration did not change signiﬁcantly
(139  33 ms vs 145  41 ms, p = 0.25; 96  20 ms vs 97  21 ms,
p = 0.33; respectively). The mean DQTc was 35  42 ms. The patient
BMI was signiﬁcantly related to QT interval prolongation (DQTc) in
the univariate analysis [95% conﬁdence interval (CI): 9.451 to
1.025, p = 0.017, Table 2]. As BMI was the only signiﬁcant parameter
in the univariate analysis, we performed a multivariate analysis using
BMI and several other parameters that may have been linked to
the DQTc, including gender and the cumulative amiodarone dose
(Table 3). BMI was recognized as an independent factor related to
DQTc in the latter analysis (95% CI: 9.240 to 0.598, p = 0.027).
Table 1
Patient characteristics and clinical valuables.
Case Age
(years)
Gender
(M/F)
BMI Basal disease
IHD/others
LVEF
(%)
VT/VF Serum K
(mequiv./l)
b-Blocker
(+)/()
Cumulative dose (mg)
AMD
Efﬁcacy
Responder/non
1 82 F 20 IHD 61 VT 5.4 (+) 859 NR
2 63 F 17 Idiopathic 62 VT 3.5 () 576 NR
3 69 F 23 Valvular 37 VT 4.7 () 562 NR
4 68 M 23 IHD 46 VT 5.6 (+) 562 NR
5 88 F 21 IHD 35 VF 3.7 () 562 NR
6 55 M 21 IHD 24 VF 4.2 (+) 288 NR
7 84 F 23 DCM 45 VT 3.9 () 1156 NR
8 74 F 31 IHD 34 VF 4.3 (+) 710 NR
9 44 F 21 Idiopathic 57 VF 3.9 () 1453 R
10 67 F 20 IHD 25 VT 4.4 (+) 710 R
11 70 M 15 IHD 21 VT 2.6 (+) 413 R
12 93 F 15 IHD 17 VF 4.6 (+) 864 R
13 73 F 22 IHD 35 VT 4.7 () 594 R
14 67 M 25 IHD 30 VF 3.5 (+) 463 R
15 86 M 16 IHD 28 VF 3.8 () 864 R
16 49 M 24 IHD 74 VF 3.2 () 734 R
17 70 M 25 IHD 49 VF 3.2 () 297 R
18 83 M 21 IHD 37 VT 4.3 (+) 1453 R
19 70 F 19 IHD 35 VF 5.1 (+) 859 R
20 55 M 23 IHD 64 VF 3.1 () 1453 R
21 61 F 25 IHD 48 VF 3.8 () 1453 R
22 76 M 24 IHD 40 VF 3.5 () 859 R
23 83 M 25 HCM 33 VT 3.9 (+) 1453 R
24 86 F 17 IHD 71 VF 3.3 () 710 R
25 57 M 26 HHD 20 VT 3.8 (+) 576 R
26 76 M 21 IHD 50 VF 4.4 (+) 384 R
27 68 M 22 HCM 57 VT 4.4 () 562 R
n = 27 71  12 14/13 22  4 19/8 42  16 12/15 4.0  0.7 13/14 794  373 19/8
AMD, amiodarone; BMI, body mass index; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; IHD, ischemic heart
disease; LVEF, left ventricular ejection fraction; R/NR, responder/non-responder; VT/VF, ventricular tachycardia/ﬁbrillation.
Fig. 2. Repolarization parameters (QTc, c-QTp, and c-Tp-e) before and during amiodarone in selected leads from two other cases (cases 9 and 27). In panel A, apparent
prolongation was observed in QTc and c-QTp (508–537 ms and 370–394 ms, respectively) without signiﬁcant change in c-Tp-e (139–143 ms). In panel B, c-QTp and c-Tp-e
were equally prolonged (312–334 ms and 114–134 ms, respectively), but there was no extreme prolongation in c-Tp-e. QTp, QRS to T-peak; Tp-e, T-peak to T-end;
repolarization indices were corrected to the heart rate by Bazett’s method (QTc, cQTp, cTp-e).
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Fig. 3. Comparison of the QTc, corrected QT to T-peak (c-QTp), and R–R interval before and during intravenous amiodarone administration. The QTc, c-QTp, and R–R intervals
were signiﬁcantly prolonged during amiodarone (476  45 ms vs 511  45 ms, p < 0.05; 338  40 ms vs 364  35 ms, p < 0.05; 762  272 ms vs 870  189 ms, p < 0.05;
respectively). QTp, QRS to T-peak; repolarization indices were corrected to the heart rate by Bazett’s method (QTc, cQTp).
p=0.25 p=0.33
Fig. 4. Comparison of the corrected T-peak to T-end (c-Tp-e) and QRS duration before and during intravenous amiodarone administration. The c-Tp-e and QRS duration did not
change signiﬁcantly (139  33 ms vs 145  41 ms, p = 0.25; 96  20 ms vs 97  21 ms, p = 0.33; respectively). Tp-e, T-peak to T-end; repolarization indices were corrected to the
heart rate by Bazett’s method (cTp-e).
Table 2
Univariate analysis for DQTc.
95% CI p value
Age 0.419 to 2.248 0.170
Gender (female) 4.385 to 27.962 0.146
BMI 9.451 to 1.025 0.017
Underlying heart disease (IHD) 17.998 to 20.496 0.895
LVEF 0.209 to 1.845 0.114
VT/VF (VF) 19.379 to 14.523 0.771
Serum K 23.862 to 24.268 0.986
b-Blocker 24.753 to 8.337 0.317
Cumulative dose (AMD) 0.041 to 0.051 0.837
Efﬁcacy 14.943 to 21.903 0.701
AMD, amiodarone; BMI, body mass index; IHD, ischemic heart disease; LVEF,
left ventricular ejection fraction; VT/VF, ventricular tachycardia/ﬁbrillation.
Table 3
Multivariate analysis for DQTc.
95% CI p value
BMI 9.240 to 0.598 0.027
Gender (female) 6.411 to 24.702 0.236
Cumulative dose (AMD) 0.038 to 0.046 0.833
AMD, amiodarone; BMI, body mass index.
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Discussion
This study demonstrated one major ﬁnding: iv-Amio homo-
geneously prolongs repolarization and properly inhibits VT/VF
recurrence without inducing TdP. Patients undergoing 12-lead ECG
examinations just before amiodarone initiation were strictly
selected for the study, and previous class I or III drugs were
prohibited to ensure that a purer pharmacologic action of iv-Amio
would be observed. To assess the electrophysiologic effect of iv-
Amio on the QT interval, we evaluated two distinct ECG
parameters, namely, QTp and Tp-e, particularly the response of
the dispersion of repolarization. QT prolongation without an
accompanying increase in dispersion of repolarization suggests
that iv-Amio elicits a uniformly prolonged action potential in
ventricular myocytes at various sites. According to the works of
Antzelevitch and colleagues [12], the transmural dispersion of
repolarization [difference between the longest APD in mid-
myocardial (M) cell and the shortest one in epicardial cell]
contributes to the genesis of T wave, and it can be estimated by
measuring Tp-e. On the contrary, Opthof et al. reported that Tp-e
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ventricle using a canine normal heart model [13]. Although two
different interpretations are being debated, both investigators
commonly accepted the theory that the Tp-e represents difference
between the longest APD and the shortest one in a ventricle.
Therefore, measuring Tp-e is thought to be one of the best methods
to evaluate the dispersion of repolarization.
Several possible mechanisms may explain the optimal action of
amiodarone on myocardial repolarization. First, amiodarone may
potently act on the IKs channel rather than the IKr channel even
during the brief period soon after intravenous injection. In
experiments with the isolated single cell of a rabbit heart
by Kamiya et al. [5], amiodarone brought about periodically
differential effects on the IK channel, namely, an IKr current
reduction in the acute phase and an IKs current reduction in the
chronic phase. Although their intriguing theory has been validated,
iv-Amio may bring about different effects in a cell-to-cell coupling
model or in human ventricular cells. According to several
experimental studies using an arterially perfused wedge prepara-
tion by Shimizu and Antzelevitch [6], the uniform response to IKs
blocker can be explained by the inhomogeneous gene expression of
the IKs channel in different ventricular cell types classiﬁed by APD
(epicardial and M cells). More IKs channels are present in the cells
with the longer APD, which helps to explain why these have a
shorter APD than other cells. Under these conditions, the same
degree of IKs inhibition in these cells presumably decreases the net
repolarizing current more in the cells with a shorter APD; hence,
the shorter APD can be prolonged to a greater extent. On the
contrary, an agent that blocks IKr prolongs the longer APD to a
signiﬁcantly greater extent and then markedly increases the
dispersion of repolarization [15], as the net repolarizing current
largely depends on IKr in the cells with the longer APD. The
response of the T wave morphology and the absence of TdP after
iv-Amio in the present study do not conﬂict with our theory that
this agent has a potent IKs-channel-blocking effect.
Second, the multi-channel- and multi-receptor-blocking beha-
viors of amiodarone can contribute to modest QT prolongation
without increasing Tp-e. Among the various functions of amiodar-
one, fast sodium-channel and slow calcium-channel blocking
effects may play an important role in inhibiting excessive QT
prolongation [16]. In experimental studies using IKr-channel-
blocking agents, mexiletine (fast sodium-channel blocker) and
verapamil (L-type calcium-channel blocker) were shown to inhibit
marked APD prolongation of the cells with longer APD by reducing
net inward currents to a certain degree [6,17].
Beta-adrenergic stimulation to myocytes under a condition
with strongly reduced IKs or IKr current elicits an inhomogeneous
prolongation of APD and TdP [18]. The anti-sympathetic effects of
amiodarone may preserve the modest prolongation of the QT
interval. The signiﬁcant R–R interval prolongation during amio-
darone might partly derive from the beta-blocking effect of this
agent. No association was found between previous beta-blocker
therapy and DQTc, even though oral beta-blocker had been used
before amiodarone in as many as 13 of the 27 patients. This can
also be explained by the relatively potent beta-blocking effect of
iv-Amio.
The present study also conﬁrmed the feasibility and efﬁcacy of
iv-Amio for patients with life-threatening VT/VF. Amiodarone
completely suppressed critical VT/VF in 70% of the patients in this
study without producing signiﬁcant side effects such as severe
hypotension, TdP, or hepatic or pulmonary toxicity, regardless of
their underlying heart disease.
The relationship between the efﬁcacy of oral amiodarone and
T wave response was investigated in a clinical study using a body
surface mapping consisting of 87 ECG leads [19]. The rate of VT/VF
recurrence was higher in the patients from the study withexcessively prolonged repolarization parameters QTc interval, QT
dispersion, and Tp-e. In the present study, however, we found no
relationship between DQTc and the efﬁcacy of intravenous
amiodarone. This discrepant result may derive from differences
in several of the clinical parameters such as the route of
administration (oral vs intravenous), the underlying patient
condition (stable vs emergent), and the number of ECG leads
obtained (87 vs 12). Our multivariate logistic regression analysis
demonstrated an association between a smaller BMI and a larger
DQTc. We infused amiodarone according to a standard protocol
that accounted for neither the body weight nor BMI of the patient.
Under a common administration protocol, the size of an organ or
ﬂuid volume of the body may inﬂuence the drug concentration in
the blood or in a targeted organ (heart). The present standard
protocol is nonetheless thought to be reasonable, as we observed
no signiﬁcant adverse effects during the amiodarone therapy
even in our patients with low BMIs. Further, a stricter protocol
according to BMI would have been impracticable in emergent
situations.
Clinical implications
Safety is one of the most important criteria for the selection of
an antiarrhythmic drug as a ﬁrst line therapy for critical cases
with life-threatening ventricular tachyarrhythmia. This study
has conﬁrmed that homogeneously prolonged repolarization
contributes greatly to the feasibility of iv-Amio by minimizing
the risk of proarrhythmia.
Study limitations
Our study had several limitations. First, the single-arm design
of this study precluded any comparison of the pharmacologic
effects of iv-Amio with control or with another type of class III
drug such as nifekalant (a pure IKr blocker). A comparison of the
particular responses of the QT interval using different types of
class III drugs may reveal a more precise ionic mechanism of
amiodarone. As mentioned earlier, a look back to previous clinical
studies testing the efﬁcacy of nifekalant would allow us to
speculate on the peculiar actions of iv-Amio. Second, our
evaluations of the QT interval and Tp-e were based solely on
the data recorded by the one ECG lead with the largest T wave
amplitude. Some investigators recommend the use of a single
unipolar (precordial) lead for evaluating the transmural disper-
sion of repolarization and advise against averaging Tp-e among
multiple leads [12,20]. Further, as previously mentioned, our
comparison of T wave parameters among all measurable
precordial ECG leads revealed no signiﬁcant differences (Fig. 1).
For these reasons, we are conﬁdent that the selected lead
generally represents the response of the myocardium to
amiodarone. Third, Bazett’s formula (a method for heart rate
correction of repolarization parameters) has been criticized for
being inaccurate at fast heart rates. Other formulas such as the
Fridericia cube-root correction and the Framingham linear
regression equation are thought to be more adequate for heart
rate correction of QT interval by some investigators [19]. However,
none of the methods has been determined as the best method
to adjust for heart rate by prospective studies. Therefore, we
used Bazett’s formula in the present study because this is the
simplest and is widely accepted by the majority of the clinical
studies.
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